Latest Insider Transactions at Madrigal Pharmaceuticals, Inc. (MDGL)
This section provides a real-time view of insider transactions for Madrigal Pharmaceuticals, Inc. (MDGL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MADRIGAL PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MADRIGAL PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 10
2025
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,470
+31.62%
|
$615,550
$65.06 P/Share
|
|
Mar 13
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,742
-0.27%
|
$2,523,892
$326.58 P/Share
|
|
Mar 13
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,742
+2.12%
|
$503,230
$65.06 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,728
-0.44%
|
$2,565,696
$332.58 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,728
+1.07%
|
$680,064
$88.06 P/Share
|
|
Mar 10
2025
|
Mardi Dier SVP and CFO |
SELL
Open market or private sale
|
Direct |
258
-2.41%
|
$83,334
$323.04 P/Share
|
|
Mar 10
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
894
+50.0%
|
-
|
|
Mar 05
2025
|
William John Sibold President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
13,066
+10.02%
|
-
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
2,061
+26.25%
|
-
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
14,113
-14.66%
|
$4,798,420
$340.42 P/Share
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
14,113
+34.14%
|
$1,227,831
$87.5 P/Share
|
|
Mar 05
2025
|
Mardi Dier SVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,784
+26.13%
|
-
|
|
Mar 05
2025
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,382
+0.94%
|
-
|
|
Mar 05
2025
|
Shannon T Kelley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,187
+23.32%
|
-
|
|
Mar 05
2025
|
Carole Huntsman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,386
+22.02%
|
-
|
|
Mar 03
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
415
-5.39%
|
$139,025
$335.0 P/Share
|
|
Mar 03
2025
|
Mardi Dier SVP and CFO |
SELL
Open market or private sale
|
Direct |
1,961
-11.72%
|
$635,364
$324.72 P/Share
|
|
Mar 03
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,834
-2.11%
|
$592,382
$323.86 P/Share
|
|
Feb 28
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
1,227
-12.86%
|
$418,407
$341.27 P/Share
|
|
Feb 27
2025
|
William John Sibold President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+32.4%
|
-
|
|
Feb 27
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
20,000
-21.4%
|
$7,100,000
$355.92 P/Share
|
|
Feb 27
2025
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+31.84%
|
$1,220,000
$61.86 P/Share
|
|
Feb 27
2025
|
James M Daly Director |
SELL
Open market or private sale
|
Direct |
15,470
-38.4%
|
$5,368,090
$347.74 P/Share
|
|
Feb 27
2025
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,470
+35.54%
|
$1,361,360
$88.06 P/Share
|
|
Jan 24
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
347
-3.22%
|
$116,245
$335.24 P/Share
|
|
Jan 24
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
1,584
-2.83%
|
$530,640
$335.24 P/Share
|
|
Jan 24
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
648
-0.14%
|
$217,080
$335.24 P/Share
|
|
Jan 24
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
103
-2.04%
|
$34,505
$335.24 P/Share
|
|
Jan 17
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
277
-3.47%
|
$75,621
$273.41 P/Share
|
|
Jan 17
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
1,689
-0.37%
|
$461,097
$273.41 P/Share
|
|
Jan 17
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
442
-8.04%
|
$120,666
$273.41 P/Share
|
|
Dec 03
2024
|
Fred B Craves Director |
SELL
Open market or private sale
|
Indirect |
3,600
-12.8%
|
$1,134,000
$315.55 P/Share
|
|
Nov 25
2024
|
Fred B Craves Director |
SELL
Open market or private sale
|
Indirect |
3,400
-9.91%
|
$1,190,000
$350.39 P/Share
|
|
Nov 21
2024
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
688
-6.0%
|
$217,408
$316.92 P/Share
|
|
Nov 07
2024
|
Richard S Levy Director |
SELL
Open market or private sale
|
Direct |
5,000
-31.23%
|
$1,750,000
$350.0 P/Share
|
|
Nov 07
2024
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.8%
|
$35,000
$7.36 P/Share
|
|
Nov 01
2024
|
Richard S Levy Director |
SELL
Open market or private sale
|
Direct |
5,000
-8.77%
|
$1,505,000
$301.97 P/Share
|
|
Nov 01
2024
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.8%
|
$35,000
$7.36 P/Share
|
|
Sep 13
2024
|
Fred B Craves Director |
SELL
Bona fide gift
|
Direct |
15,000
-4.0%
|
-
|
|
Sep 09
2024
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
6,363
-10.22%
|
$1,546,209
$243.83 P/Share
|
|
Aug 15
2024
|
Shannon T Kelley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,215
+39.52%
|
-
|
|
Jun 25
2024
|
Kenneth Bate Director |
BUY
Grant, award, or other acquisition
|
Direct |
714
+27.19%
|
-
|
|
Jun 25
2024
|
Fred B Craves Director |
BUY
Grant, award, or other acquisition
|
Direct |
714
+0.19%
|
-
|
|
Jun 25
2024
|
Paul A Friedman |
BUY
Grant, award, or other acquisition
|
Direct |
714
+0.38%
|
-
|
|
Jun 25
2024
|
Richard S Levy Director |
BUY
Grant, award, or other acquisition
|
Direct |
714
+6.09%
|
-
|
|
Jun 25
2024
|
James M Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
714
+27.19%
|
-
|
|
Jun 25
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
2,856
+0.42%
|
-
|
|
Jun 14
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
1,900
-25.68%
|
$532,000
$280.0 P/Share
|
|
Jun 14
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+20.43%
|
$165,300
$87.09 P/Share
|
|
Jun 12
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
2,000
-26.67%
|
$570,000
$285.0 P/Share
|